ABSTRACT
Transaldolase deficiency predisposes to chronic liver disease progressing from cirrhosis to hepatocellular carcinoma (HCC). Transition from cirrhosis to hepatocarcinogenesis depends on mitochondrial oxidative stress, as controlled by cytosolic aldose metabolism through the pentose phosphate pathway (PPP). Progression to HCC is critically dependent on NADPH depletion and polyol buildup by aldose reductase (AR), while this enzyme protects from carbon trapping in the PPP and growth restriction in TAL deficiency. Although AR inactivation blocked susceptibility to hepatocarcinogenesis, it enhanced growth restriction, carbon trapping in the non-oxidative branch of the PPP and failed to reverse the depletion of glucose 6-phosphate (G6P) and liver cirrhosis. Here, we show that inactivation of the TAL-AR axis results in metabolic stress characterized by reduced mitophagy, enhanced overall autophagy, activation of the mechanistic target of rapamycin (mTOR), diminished glycosylation and secretion of paraoxonase 1 (PON1), production of antiphospholipid autoantibodies (aPL), loss of CD161+ NK cells, and expansion of CD38+ Ito cells, which are responsive to treatment with rapamycin in vivo. The present study thus identifies glycosylation and secretion of PON1 and aPL production as mTOR-dependent regulatory checkpoints of autoimmunity underlying liver cirrhosis in TAL deficiency.
ABSTRACT
Oxidative stress modulates carcinogenesis in the liver; however, direct evidence for metabolic control of oxidative stress during pathogenesis, particularly, of progression from cirrhosis to hepatocellular carcinoma (HCC), has been lacking. Deficiency of transaldolase (TAL), a rate-limiting enzyme of the non-oxidative branch of the pentose phosphate pathway (PPP), restricts growth and predisposes to cirrhosis and HCC in mice and humans. Here, we show that mitochondrial oxidative stress and progression from cirrhosis to HCC and acetaminophen-induced liver necrosis are critically dependent on NADPH depletion and polyol buildup by aldose reductase (AR), while this enzyme protects from carbon trapping in the PPP and growth restriction in TAL deficiency. Both TAL and AR are confined to the cytosol; however, their inactivation distorts mitochondrial redox homeostasis in opposite directions. The results suggest that AR acts as a rheostat of carbon recycling and NADPH output of the PPP with broad implications for disease progression from cirrhosis to HCC.
Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Humans , Animals , Mice , Carcinoma, Hepatocellular/pathology , Cytosol/pathology , NADP , Liver Neoplasms/pathology , Carcinogenesis/pathology , Liver Cirrhosis/pathologyABSTRACT
The rs1076560 polymorphism of DRD2 (encoding dopamine receptor D2) is associated with alternative splicing and cognitive functioning; however, a mechanistic relationship to schizophrenia has not been shown. Here, we demonstrate that rs1076560(T) imparts a small but reliable risk for schizophrenia in a sample of 616 affected families and five independent replication samples totaling 4017 affected and 4704 unaffected individuals (odds ratio=1.1; P=0.004). rs1076560(T) was associated with impaired verbal fluency and comprehension in schizophrenia but improved performance among healthy comparison subjects. rs1076560(T) also associated with lower D2 short isoform expression in postmortem brain. rs1076560(T) disrupted a binding site for the splicing factor ZRANB2, diminished binding affinity between DRD2 pre-mRNA and ZRANB2 and abolished the ability of ZRANB2 to modulate short:long isoform-expression ratios of DRD2 minigenes in cell culture. Collectively, this work implicates rs1076560(T) as one possible risk factor for schizophrenia in the Han Chinese population, and suggests molecular mechanisms by which it may exert such influence.
Subject(s)
Receptors, Dopamine D2/genetics , Schizophrenia/genetics , Adult , Alleles , Alternative Splicing/genetics , Brain/metabolism , China , Cognition/physiology , Ethnicity/genetics , Female , Genetic Predisposition to Disease/genetics , Genotype , Humans , Male , Polymorphism, Single Nucleotide/genetics , RNA Precursors/metabolism , RNA Splicing , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Receptors, Dopamine D2/metabolism , Risk Factors , Schizophrenia/metabolismABSTRACT
Two-stage revision surgery for infected total knee replacement offers the highest rate of success for the elimination of infection. The use of articulating antibiotic-laden cement spacers during the first stage to eradicate infection also allows protection of the soft tissues against excessive scarring and stiffness. We have investigated the effect of cyclical loading of cement spacers on the elution of antibiotics. Femoral and tibial spacers containing vancomycin at a constant concentration and tobramycin of varying concentrations were studied in vitro. The specimens were immersed and loaded cyclically to 250 N, with a flexion excursion of 45°, for 35 000 cycles. The buffered solution was sampled at set intervals and the antibiotic concentration was established so that the elution could be calculated. Unloaded samples were used as a control group for statistical comparison. The elution of tobramycin increased proportionately with its concentration in cement and was significantly higher at all sampling times from five minutes to 1680 minutes in loaded components compared with the control group (p = 0.021 and p = 0.003, respectively). A similar trend was observed with elution of vancomycin, but this failed to reach statistical significance at five, 1320 and 1560 minutes (p = 0.0508, p = 0.067 and p = 0.347, respectively). However, cyclically loaded and control components showed an increased elution of vancomycin with increasing tobramycin concentration in the specimens, despite all components having the same vancomycin concentration. The concentration of tobramycin influences both tobramycin and vancomycin elution from bone cement. Cyclical loading of the cement spacers enhanced the elution of vancomycin and tobramycin.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Bone Cements/chemistry , Knee Prosthesis/adverse effects , Prosthesis-Related Infections/drug therapy , Arthroplasty, Replacement, Knee , Combined Modality Therapy , Dose-Response Relationship, Drug , Humans , Knee Joint/physiopathology , Materials Testing/methods , Polymethyl Methacrylate , Prosthesis-Related Infections/surgery , Reoperation , Stress, Mechanical , Tobramycin/administration & dosage , Vancomycin/administration & dosageABSTRACT
UNLABELLED: Osteoporosis after spinal cord injury is common. Reductions in bone density are rapid and fracture rates are higher after injury. Early treatment with 4 mg zoledronic acid significantly reduced bone loss at the hip compared to untreated individuals in the first year. Treatment appeared safe and well tolerated. INTRODUCTION: Bone mineral density (BMD) is lost rapidly following spinal cord injury (SCI), predominantly in the lower limbs. Bone turnover markers suggest an early increase in resorption. METHODS: A randomised, open-label study of 14 patients with acute SCI randomised to receive 4 mg IV zoledronic acid or standard treatment. BMD was measured by dual-X-ray absorptiometry at the lumbar spine and hip (femoral neck, total and trochanter) at baseline, 3, 6 and 12 months. Bone turnover markers (serum C-terminal telopeptide and Procollagen I N-terminal peptide and urinary N-terminal telopeptide/Cr ratio) were also measured. RESULTS: After 12 months, there was a significant difference in BMD between the groups at the total hip (12.4%, p = 0.005), trochanter (13.4%, p = 0.028) and lumbar spine (2.7%, p = 0.033). However, the difference between groups at the femoral neck was not significant (4.8%, p = 0.741). In the treated group, bone resorption was reduced and remained reduced up to 12 months. Other than flu-like symptoms immediately after the infusion, no adverse events were observed. CONCLUSION: IV zoledronic acid is an effective and well-tolerated treatment to prevent bone mineral density loss at the total hip and trochanter for up to 12 months following SCI.
Subject(s)
Bone Density Conservation Agents/administration & dosage , Diphosphonates/administration & dosage , Imidazoles/administration & dosage , Osteoporosis/prevention & control , Spinal Cord Injuries/complications , Adolescent , Adult , Biomarkers/metabolism , Bone Density/drug effects , Bone Density Conservation Agents/therapeutic use , Bone Resorption/etiology , Bone Resorption/prevention & control , Bone and Bones/metabolism , Diphosphonates/therapeutic use , Drug Administration Schedule , Female , Follow-Up Studies , Hip Joint/physiopathology , Humans , Imidazoles/therapeutic use , Lumbar Vertebrae/physiopathology , Male , Osteoporosis/etiology , Osteoporosis/physiopathology , Spinal Cord Injuries/physiopathology , Young Adult , Zoledronic AcidABSTRACT
The spontaneously hypertensive rat (SHR/NCrl) is a validated model of attention-deficit/hyperactivity disorder (ADHD) combined subtype, whereas a recently identified substrain of the Wistar Kyoto rat (WKY/NCrl) is a model of ADHD inattentive subtype. In this study, we first examined the expression of genes involved in dopamine signaling and metabolism in the dorsal striatum and ventral mesencephalon of these two rat strains, as well as three reference control strains (WKY/NHsd, WK/HanTac, and SD/NTac) using quantitative real time RT-PCR. Next, striatal dopamine transporter (DAT) density was determined by ligand binding assay in the two ADHD-like strains at different developmental stages and after methylphenidate treatment. In adult rats, the mRNA expression of DAT and tyrosine hydroxylase was elevated in SHR/NCrl and WKY/NCrl rats compared to control strains, with differences between SHR/NCrl and WKY/NCrl rats also evident. During normal development, changes of striatal DAT densities occurred in both strains with lower densities in WKY/NCrl compared to SHR/NCrl after day 25. Two-weeks methylphenidate treatment during different developmental stages was associated with decreased striatal DAT density in both rat strains compared to the non-treated rats with more pronounced effects followed prepubertal treatment. These results suggest differences in the pathophysiology of the combined versus the predominantly inattentive animal model of ADHD. Finally, treatment with methylphenidate might reduce elevated DAT levels more effectively in the combined subtype especially when applied before puberty.
Subject(s)
Attention Deficit Disorder with Hyperactivity/metabolism , Attention , Dopamine Plasma Membrane Transport Proteins/metabolism , Dopamine Uptake Inhibitors/pharmacology , Methylphenidate/pharmacology , Animals , Attention Deficit Disorder with Hyperactivity/psychology , Corpus Striatum/metabolism , Dopamine Plasma Membrane Transport Proteins/genetics , Male , RNA, Messenger/metabolism , Radioligand Assay , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Rats, Sprague-Dawley , Rats, Wistar , Receptors, Dopamine D1/genetics , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/metabolism , Species Specificity , Time FactorsABSTRACT
STUDY DESIGN: Investigation of bowel function in 55 patients and 26 healthy volunteers using radiological, anorectal physiological and laser Doppler blood flow monitoring. OBJECTIVES: Bowel dysfunction is common after spinal cord injury (SCI). We aimed to determine whether hindgut testing of autonomic innervation provides insight into presence of symptoms, altered motor function (transit) and level of injury. SETTING: St Mark's Hospital, UK and The Spinal Injuries Unit, Royal National Orthopaedic Hospital, UK. METHODS: A total of 55 patients with chronic complete SCI and 26 healthy volunteers were studied. Twenty-four patients had lesions above T5 and 31 had lesions below T5. Thirty-five patients complained of constipation: 75% (18/24) of patients with lesions above T5 and 55% (17/31) of those with lesions below T5. Gut transit, rectal electrosensitivity and rectal blood flow were measured. RESULTS: Slow gut transit occurred in 65% of patients and in all the 35 patients complaining of constipation. Delay was pancolonic. All patients had an elevated sensory threshold. The threshold was significantly higher in those with subjective constipation (P<0.01), slow transit (P<0.04) and high SCI (P=0.046). Mucosal blood flow was lower in SCI patients with constipation (P<0.04) and slow transit (P<0.03). It was higher than normal in high-SCI volunteers (P=0.056), reflecting loss of sympathetic inhibition. CONCLUSIONS: In SCI, subjective constipation correlates closely with slow gut transit. Delay is pancolonic, regardless of the site of lesion. Sensory testing provides evidence for completeness of lesion, offering further evidence for pain transmission through sympathetic pathways. Studies in SCI patients provide further evidence of mucosal blood flow as a marker of altered autonomic innervation.
Subject(s)
Autonomic Nervous System/physiopathology , Intestinal Diseases/etiology , Intestinal Diseases/physiopathology , Spinal Cord Injuries/complications , Spinal Cord Injuries/physiopathology , Adult , Constipation/etiology , Constipation/physiopathology , Female , Gastrointestinal Transit/physiology , Humans , Intestine, Large/blood supply , Intestine, Large/physiopathology , Laser-Doppler Flowmetry , Male , Manometry , Middle Aged , Pain Threshold , Young AdultABSTRACT
INTRODUCTION: Increased body mass index (BMI) is associated with the development of osteoarthritis of the hip. Many overweight patients with an arthritic hip cite restricted mobility and pain as impeding factors in their attempts to lose weight. There is an assumption that weight loss will occur after their surgery due to increased mobility. PATIENTS AND METHODS: The records of 180 patients who had undergone total hip arthroplasty (THA) were reviewed to identify BMI prior to, and 2 years after, surgery. RESULTS: BMI significantly increased postoperatively, both in patients with a pre-operative BMI in the recommended range (P < 0.001) and in those whose pre-operative BMI was indicative of obesity (P = 0.01). CONCLUSIONS: Irrespective of pre-operative BMI, reduction in body mass index did not occur following hip replacement surgery.
Subject(s)
Arthroplasty, Replacement, Hip , Osteoarthritis, Hip/surgery , Weight Loss , Adult , Aged , Aged, 80 and over , Body Mass Index , Female , Humans , Male , Middle Aged , Preoperative Care/methodsABSTRACT
BACKGROUND: The "Lister family complex," an extensive Swedish family with autosomal dominant Parkinson disease, was first described by Henry Mjönes in 1949. On the basis of clinical, molecular, and genealogic findings on a Swedish and an American family branch, we provide genetic evidence that explains the parkinsonism in this extended pedigree. METHODS: Clinical methods included a detailed neurologic exam of the proband of the Swedish family branch, MRI, and ([123]I)-beta-CIT SPECT imaging. Genomic analysis included alpha-synuclein sequencing, SNCA real-time PCR dosage, chromosome 4q21 microsatellite analysis, and high-resolution microarray genotyping. The geographic origin and ancestral genealogy of each pedigree were researched in the medical literature and Swedish Parish records. RESULTS: The proband of the Swedish family branch presented with early dysautonomia followed by progressive parkinsonism suggestive of multiple system atrophy. Molecular analysis identified a genomic duplication of <0.9 Mb encompassing alpha-synuclein and multimerin 1 (SNCA-MMRN1), flanked by long interspersed repeat sequences (LINE L1). Microsatellite variability within the genomic interval was identical to that previously described for a Swedish American family with an alpha-synuclein triplication. Subsequent genealogic investigation suggested that both kindreds are ancestrally related to the Lister family complex. CONCLUSION: Our findings extend clinical, genetic, and genealogical research on the Lister family complex. The genetic basis for familial parkinsonism is an SNCA-MMRN11 multiplication, but whereas SNCA-MMRN1 duplication in the Swedish proband (Branch J) leads to late-onset autonomic dysfunction and parkinsonism, SNCA-MMRN1 triplication in the Swedish American family (Branch I) leads to early-onset Parkinson disease and dementia.
Subject(s)
Blood Proteins/genetics , Dementia/genetics , Genetic Predisposition to Disease/genetics , Mutation/genetics , Parkinsonian Disorders/genetics , alpha-Synuclein/genetics , Adult , Aged , Americas , Autonomic Nervous System Diseases/genetics , Autonomic Nervous System Diseases/physiopathology , Chromosomes, Human, Pair 4/genetics , DNA Mutational Analysis , Dementia/physiopathology , Female , Gene Dosage , Genealogy and Heraldry , Genetic Testing , Humans , Male , Microsatellite Repeats/genetics , Middle Aged , Oligonucleotide Array Sequence Analysis , Parkinsonian Disorders/diagnosis , Parkinsonian Disorders/physiopathology , Pedigree , Phenotype , Sweden , Tomography, Emission-Computed, Single-PhotonABSTRACT
The search for DNA alterations that cause human disease has been an area of active research for more than 50 years, since the time that the genetic code was first solved. In the absence of data implicating chromosomal aberrations, researchers historically have performed whole genome linkage analysis or candidate gene association analysis to develop hypotheses about the genes that most likely cause a specific phenotype or disease. Whereas whole genome linkage analysis examines all chromosomal locations without a priori predictions regarding what genes underlie susceptibility, candidate gene association studies require a researcher to know in advance the genes that he or she wishes to test (based on their knowledge of a disease). To date, very few whole genome linkage studies and candidate gene studies have produced results that lead to generalizable findings about common diseases. One factor contributing to this lack of results has certainly been the previously limited resolution of the techniques. Recent technological advances, however, have made it possible to perform highly informative whole genome linkage and association analyses, as well as whole genome transcription (transcriptome) analysis. In addition, for the first time we can detect structural DNA aberrations throughout the genome on a fine scale. Each of these four approaches has its own strengths and weaknesses, but taken together, the results from an integrated analysis can implicate highly promising novel candidate genes. Here, we provide an overview of the integrated methodology that we have used to combine high-throughput genetic and functional genomic data with bioinformatics data that have produced new insights into the potential biological basis for schizophrenia. We believe that the potential of this combined approach is greater than that of a single mode of discovery, particularly for complex genetic diseases.
Subject(s)
Computational Biology , Genomics , Schizophrenia/genetics , Systems Biology/methods , Animals , Genome/genetics , HumansABSTRACT
The intra-articular injection of local anaesthetic is frequently used for pain relief after arthroscopy. There is, however, no published evidence of the analgesic effect of bupivacaine in the ankle. In a randomised, double-blind study, 35 patients undergoing arthroscopy of the ankle were allocated to receive intra-articular saline or bupivacaine. Pain was assessed using pain scores and additional analgesic requirements. Intra-articular bupivacaine had a significant analgesic effect in the immediate post-operative period, reducing pain scores and the need for additional analgesics. We recommend the use of intra-articular bupivacaine for post-operative analgesia in ankle surgery.
Subject(s)
Anesthetics, Local/administration & dosage , Ankle Joint/surgery , Arthroscopy , Bupivacaine/administration & dosage , Pain, Postoperative/prevention & control , Adult , Aged , Double-Blind Method , Female , Humans , Injections, Intra-Articular , Male , Middle Aged , Pain Measurement/methods , Postoperative Care/methods , Prospective StudiesABSTRACT
As metal-on-metal arthroplasty becomes more widespread, concerns are being raised about the potential dangers of metal particulate debris. We present the case of a benign psoas mass secondary to the presence of such particles. The mass was excised and the hip resurfacing subsequently revised to a total hip replacement.
Subject(s)
Arthroplasty, Replacement, Hip/methods , Psoas Muscles , Soft Tissue Neoplasms/diagnosis , Arthroplasty, Replacement, Hip/adverse effects , Female , Hip Joint , Humans , Metals/adverse effects , Middle Aged , Reoperation , Soft Tissue Neoplasms/etiology , Soft Tissue Neoplasms/surgery , Treatment OutcomeSubject(s)
Bone Wires , Fracture Fixation/methods , Humeral Fractures/surgery , Elbow Joint , Humans , HumerusABSTRACT
We previously performed a genome-wide linkage scan in Portuguese schizophrenia families that identified a risk locus on chromosome 5q31-q35. This finding was supported by meta-analysis of 20 other schizophrenia genome-wide scans that identified 5q23.2-q34 as the second most compelling susceptibility locus in the genome. In the present report, we took a two-stage candidate gene association approach to investigate a group of gamma-aminobutyric acid (GABA) A receptor subunit genes (GABRA1, GABRA6, GABRB2, GABRG2, and GABRP) within our linkage peak. These genes are plausible candidates based on prior evidence for GABA system involvement in schizophrenia. In the first stage, associations were detected in a Portuguese patient sample with single nucleotide polymorphisms (SNPs) and haplotypes in GABRA1 (P=0.00062-0.048), GABRP (P=0.0024-0.042), and GABRA6 (P=0.0065-0.0088). The GABRA1 and GABRP findings were replicated in the second stage in an independent German family-based sample (P=0.0015-0.043). Supportive evidence for association was also obtained for a previously reported GABRB2 risk haplotype. Exploratory analyses of the effects of associated GABRA1 haplotypes on transcript levels found altered expression of GABRA6 and coexpressed genes of GABRA1 and GABRB2. Comparison of transcript levels in schizophrenia patients and unaffected siblings found lower patient expression of GABRA6 and coexpressed genes of GABRA1. Interestingly, the GABRA1 coexpressed genes include synaptic and vesicle-associated genes previously found altered in schizophrenia prefrontal cortex. Taken together, these results support the involvement of the chromosome 5q GABAA receptor gene cluster in schizophrenia, and suggest that schizophrenia-associated haplotypes may alter expression of GABA-related genes.
Subject(s)
Chromosomes, Human, Pair 5/genetics , Genetic Predisposition to Disease/genetics , Receptors, GABA-A/genetics , Schizophrenia/genetics , Chromosome Mapping , Germany , Haplotypes , Humans , Linkage Disequilibrium , Oligonucleotide Array Sequence Analysis , Pedigree , Polymorphism, Single Nucleotide , Portugal , Reference ValuesSubject(s)
Electric Stimulation Therapy/adverse effects , Electrodes, Implanted/adverse effects , Spinal Cord Injuries/therapy , Spinal Fractures/etiology , Bone Density , Bone Diseases, Metabolic/complications , Fecal Incontinence/prevention & control , Fecal Incontinence/therapy , Humans , Patient Selection , Risk Factors , Sacrum , Spinal Cord Injuries/physiopathology , Spinal Fractures/pathology , Spinal Fractures/physiopathology , Spinal Nerve Roots/physiology , Spondylolisthesis/complications , Urinary Incontinence/prevention & control , Urinary Incontinence/therapyABSTRACT
Schizophrenia is a common, multigenic psychiatric disorder. Linkage studies, including a recent meta-analysis of genome scans, have repeatedly implicated chromosome 8p12-p23.1 in schizophrenia susceptibility. More recently, significant association with a candidate gene on 8p12, neuregulin 1 (NRG1), has been reported in several European and Chinese samples. We investigated NRG1 for association in schizophrenia patients of Portuguese descent to determine whether this gene is a risk factor in this population. We tested NRG1 markers and haplotypes for association in 111 parent-proband trios, 321 unrelated cases, and 242 control individuals. Associations were found with a haplotype that overlaps the risk haplotype originally reported in the Icelandic population ("Hap(ICE)"), and two haplotypes located in the 3' end of NRG1 (all P<0.05). However, association was not detected with Hap(ICE) itself. Comparison of NRG1 transcript expression in peripheral leukocytes from schizophrenia patients and unaffected siblings identified 3.8-fold higher levels of the SMDF variant in patients (P=0.039). Significant positive correlations (P<0.001) were found between SMDF and HRG-beta 2 expression and between HRG-gamma and ndf43 expression, suggesting common transcriptional regulation of NRG1 variants. In summary, our results suggest that haplotypes across NRG1 and multiple NRG1 variants are involved in schizophrenia.
Subject(s)
Chromosomes, Human, Pair 8/genetics , Nerve Tissue Proteins/genetics , Neuregulin-1/genetics , Schizophrenia/ethnology , Schizophrenia/genetics , Chromosome Mapping , Family , Female , Genetic Linkage , Genetic Predisposition to Disease/ethnology , Genomics , Haplotypes , Humans , Male , Microsatellite Repeats/genetics , Pedigree , Polymorphism, Single Nucleotide , Portugal/epidemiology , Reference Values , White People/geneticsABSTRACT
We performed a linkage analysis on 25 extended multiplex Portuguese families segregating for bipolar disorder, by use of a high-density single-nucleotide-polymorphism (SNP) genotyping assay, the GeneChip Human Mapping 10K Array (HMA10K). Of these families, 12 were used for a direct comparison of the HMA10K with the traditional 10-cM microsatellite marker set and the more dense 4-cM marker set. This comparative analysis indicated the presence of significant linkage peaks in the SNP assay in chromosomal regions characterized by poor coverage and low information content on the microsatellite assays. The HMA10K provided consistently high information and enhanced coverage throughout these regions. Across the entire genome, the HMA10K had an average information content of 0.842 with 0.21-Mb intermarker spacing. In the 12-family set, the HMA10K-based analysis detected two chromosomal regions with genomewide significant linkage on chromosomes 6q22 and 11p11; both regions had failed to meet this strict threshold with the microsatellite assays. The full 25-family collection further strengthened the findings on chromosome 6q22, achieving genomewide significance with a maximum nonparametric linkage (NPL) score of 4.20 and a maximum LOD score of 3.56 at position 125.8 Mb. In addition to this highly significant finding, several other regions of suggestive linkage have also been identified in the 25-family data set, including two regions on chromosome 2 (57 Mb, NPL = 2.98; 145 Mb, NPL = 3.09), as well as regions on chromosomes 4 (91 Mb, NPL = 2.97), 16 (20 Mb, NPL = 2.89), and 20 (60 Mb, NPL = 2.99). We conclude that at least some of the linkage peaks we have identified may have been largely undetected in previous whole-genome scans for bipolar disorder because of insufficient coverage or information content, particularly on chromosomes 6q22 and 11p11.
Subject(s)
Bipolar Disorder/genetics , Chromosomes, Human, Pair 6/genetics , Genetic Linkage , Genome, Human , Polymorphism, Single Nucleotide/genetics , Chromosomes, Human, Pair 11/genetics , Family , Female , Genotype , Haplotypes , Humans , Lod Score , Male , Microsatellite RepeatsABSTRACT
OVERVIEW: The National Acute Spinal Cord Injury Studies (NASCIS II and III) and the Cochrane review advocate the administration of high dose methylprednisolone following acute traumatic spinal cord injury. OBJECTIVE: To determine the actual use and correct implementation of the NASCIS protocols in patients referred to a regional spinal injuries unit. DESIGN: Observational study on the timing and correct dosage of methylprednisolone. The admission Frankel grade, American Spinal Injury Association (ASIA) neurological classification were recorded prospectively. SUBJECTS: The 100 consecutive patients with complete or incomplete spinal cord injuries (Frankel grade A-D) were studied over a 2 years period. MAIN OUTCOME MEASURE: Correct administration of methylprednisolone according to the NASCIS protocols. RESULTS: During the study period only 25% of the patients admitted to our spinal injuries unit received methylprednisolone at the referring hospital according to the NASCIS protocols. An additional 10 patients were given methylprednisolone incorrectly. CONCLUSION: Evidence based medicine is not being practiced in the management of patients with acute spinal cord injury.